The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
DRAM1 increases the secretion of PKM2-enriched EVs from hepatocytes to promote macrophage activation and disease progression in ALD
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ApoE/hAAT promoter is known for its strong and liver-specific expression, which has been demonstrated in previous studies to provide effective gene regulation specifically within hepatocytes56,57,104.”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [56]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ApoE/hAAT promoter is known for its strong and liver-specific expression, which has been demonstrated in previous studies to provide effective gene regulation specifically within hepatocytes56,57,104.”
From ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver (2025) · cites this paper as [56]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.005 · Cited by 1,397
DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis
Crighton, D., Wilkinson, S., O'Prey, J., Syed, N., Smith, P., Harrison, P. R., Gasco, M., Garrone, O., Crook, T., & Ryan, K. M. (2006) · Cell · doi:10.1016/j.cell.2006.05.034 · Cited by 1,380
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Gut–Liver Axis in Alcoholic Liver Disease
Szabo, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.042 · Cited by 754
Flagged first, then by citations
Research works printed but not linked: 40
- Wei, 2019, DRAM1 deficiency affects the organization and function of the Golgi apparatus, Cell. Signal., 63, 109375, 10.1016/j.cellsig.2019.109375 · DOI
- Kerley-Hamilton, 2007, The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins, Biochim. Biophys. Acta., 1769, 209, 10.1016/j.bbaexp.2007.02.002 · DOI
- Liu, 2013, Depending on the stage of hepatosteatosis, p53 causes apoptosis primarily through either DRAM-induced autophagy or BAX, Liver Int., 33, 1566, 10.1111/liv.12238 · DOI
- Tang, 2019, Effect of autophagy gene DRAM on proliferation, cell cycle, apoptosis, and autophagy of osteoblast in osteoporosis rats, J. Cell. Physiol., 234, 5023, 10.1002/jcp.27304 · DOI · Paper page
- Memmert, 2018, Damage-regulated autophagy modulator 1 in oral inflammation and infection, Clin. Oral Investig., 22, 2933, 10.1007/s00784-018-2381-6 · DOI
- Avila, 2020, Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting, Gut, 69, 764, 10.1136/gutjnl-2019-319720 · DOI
- Thursz, 2019, Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study, J. Hepatol., 70, 521, 10.1016/j.jhep.2018.10.041 · DOI
- Griswold, 2018, Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 392, 1015, 10.1016/S0140-6736(18)31310-2 · DOI · Paper page
- Kong, 2019, Pathogenesis, early diagnosis, and therapeutic management of alcoholic liver disease, Int. J. Mol. Sci., 20, 2712, 10.3390/ijms20112712 · DOI
- Amini, 2010, Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World, J. Gastroenterol., 16, 4905
- Naveau, 2004, A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis, Hepatology, 39, 1390, 10.1002/hep.20206 · DOI
- Verma, 2016, Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles, J. Hepatol., 64, 651, 10.1016/j.jhep.2015.11.020 · DOI
- Ge, 2014, Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice, Hepatology, 59, 1600, 10.1002/hep.26931 · DOI
- Dou, 2019, Macrophage phenotype and function in liver disorder, Front. Immunol., 10, 3112, 10.3389/fimmu.2019.03112 · DOI
- Li, 2020, DNMT3b-mediated methylation of ZSWIM3 enhances inflammation in alcohol-induced liver injury via regulating TRAF2-mediated NF-κB pathway, Clin. Sci. (Lond)., 134, 1935, 10.1042/CS20200031 · DOI
- Slevin, 2020, Kupffer cells: inflammation pathways and cell-cell interactions in alcohol-associated liver disease, Am. J. Pathol., 190, 2185, 10.1016/j.ajpath.2020.08.014 · DOI
- Kong, 2019, HSPA12A is a novel player in nonalcoholic steatohepatitis via promoting nuclear PKM2-mediated M1 macrophage polarization, Diabetes, 68, 361, 10.2337/db18-0035 · DOI
- Elsharkasy, 2020, Extracellular vesicles as drug delivery systems: Why and how?, Adv. Drug Deliv. Rev., 159, 332, 10.1016/j.addr.2020.04.004 · DOI
- Mead, 2020, Extracellular vesicle therapy for retinal diseases, Prog. Retin. Eye Res., 79, 100849, 10.1016/j.preteyeres.2020.100849 · DOI
- Azparren-Angulo, 2021, Extracellular vesicles in hepatology: physiological role, involvement in pathogenesis, and therapeutic opportunities, Pharmacol. Ther., 218, 107683, 10.1016/j.pharmthera.2020.107683 · DOI
- Thietart, 2020, Extracellular vesicles as biomarkers in liver diseases: a clinician's point of view, J. Hepatol., 73, 1507, 10.1016/j.jhep.2020.07.014 · DOI
- Mandrekar, 2009, Signalling pathways in alcohol-induced liver inflammation, J. Hepatol., 50, 1258, 10.1016/j.jhep.2009.03.007 · DOI
- Kreimer, 2015, Mass-spectrometry-based molecular characterization of extracellular vesicles: lipidomics and proteomics, J. Proteome. Res., 14, 2367, 10.1021/pr501279t · DOI
- Hou, 2020, Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment, Mol. Cell., 78, 1192, 10.1016/j.molcel.2020.05.004 · DOI
- Ni, 2012, Serum starvation induces DRAM expression in liver cancer cells via histone modifications within its promoter locus, PLoS. One., 7, 10.1371/journal.pone.0050502 · DOI
- Yu, 2014, DRAM1 protects neuroblastoma cells from oxygen-glucose deprivation/reperfusion-induced injury via autophagy, Int. J. Mol. Sci., 15, 19253, 10.3390/ijms151019253 · DOI
- Xu, 2019, DRAM is involved in hypoxia/ischemia-induced autophagic apoptosis in hepatocytes, Aging Dis., 10, 82, 10.14336/AD.2018.0210 · DOI
- Xu, 2018, Protective effects of taraxasterol against ethanol-induced liver injury by regulating CYP2E1/Nrf2/HO-1 and NF-κB signaling pathways in mice, Oxid. Med. Cell. Longev., 2018, 8284107, 10.1155/2018/8284107 · DOI
- Sangineto, 2020, Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease, Liver Int., 40, 1610, 10.1111/liv.14483 · DOI
- Ho, 2019, Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress, Cell. Death Discov., 5, 131, 10.1038/s41420-019-0211-5 · DOI
- Ahn, 2010, Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer, Oncogene, 29, 1155, 10.1038/onc.2009.413 · DOI
- Yu, 2019, Loss of p53 sensitizes cells to palmitic acid-induced apoptosis by reactive oxygen species accumulation, Int. J. Mol. Sci., 20, 6268, 10.3390/ijms20246268 · DOI
- Yuan, 2020, Vitexin protects against ethanol-induced liver injury through Sirt1/p53 signaling pathway, Eur. J. Pharmacol., 873, 173007, 10.1016/j.ejphar.2020.173007 · DOI
- Yan, 2018, p53 as a double-edged sword in the progression of non-alcoholic fatty liver disease, Life Sci., 215, 64, 10.1016/j.lfs.2018.10.051 · DOI
- McGill, 1999, p53 and cancer therapy: a double-edged sword, J. Clin. Invest., 104, 223, 10.1172/JCI7861 · DOI
- Alquraishi, 2019, Pyruvate kinase M2: a simple molecule with complex functions, Free Radic. Biol. Med., 143, 176, 10.1016/j.freeradbiomed.2019.08.007 · DOI
- Hsu, 2018, Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling, Mol. Cancer, 17, 35, 10.1186/s12943-018-0791-3 · DOI
- Yang, 2014, PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis, Nat. Commun., 5, 4436, 10.1038/ncomms5436 · DOI
- Meoli, 2018, Nonalcoholic fatty liver disease and gastric bypass surgery regulate serum and hepatic levels of pyruvate kinase isoenzyme M2, Am. J. Physiol. Endocrinol. Metab., 315, E613, 10.1152/ajpendo.00296.2017 · DOI
- Amin, 2019, Pyruvate kinase M2: a multifarious enzyme in non-canonical localization to promote cancer progression, Biochim. Biophys. Acta. Rev. Cancer, 1871, 331, 10.1016/j.bbcan.2019.02.003 · DOI
Cited by
Sorted by citations
Chen, J., Huang, H., Chen, C., Xia, G., Huang, H., Xiong, Y., Luo, P., Chen, Y., Li, J., Wen, L., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08818-x · Cited by 1
Metadata
- Authors
- Tan, J., Zhang, J., Wang, M., Wang, Y., Dong, M., Ma, X., Sun, B., Liu, S., Zhao, Z., Chen, L., Jin, W., Liu, K., Xin, Y., & Zhuang, L.
- Venue
- Molecular Therapy Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 27
- Pages
- 375-389
- ISSN
- 2162-2531
- PMC
- PMC8728309
- Cited by
- 26
- References
- 5
- Language
- en
- Licence
- Funders
- National Natural Science Foundation of China (31770837, 81873976)
- Department of Science and Technology of Shandong Province
- Key Technology Research and Development Program of Shandong (2019GSF108148)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review